Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.
de Lazzari E, Negredo EB, Domingo P, Tiraboschi JM, Ribera E, Abdulghani N, Alba V, Fernández-Arroyo S, Viladés C, Peraire J, Gatell JM, Blanco JL, Vidal F, Rull A, Martinez E. de Lazzari E, et al. Among authors: abdulghani n. J Antimicrob Chemother. 2024 May 2;79(5):1133-1141. doi: 10.1093/jac/dkae083. J Antimicrob Chemother. 2024. PMID: 38546974 Free PMC article. Clinical Trial.
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J, de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, Puig J, Mateo MG, Podzamczer D, Gutierrez MM, Paredes R, Clotet B, Gatell JM, Blanco JL, Martínez E; DOLAM study group. Rojas J, et al. Among authors: abdulghani n. Lancet HIV. 2021 Aug;8(8):e463-e473. doi: 10.1016/S2352-3018(21)00100-4. Lancet HIV. 2021. PMID: 34358497 Clinical Trial.
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens.
Burgos J, Moreno-Fornés S, Reyes-Urueña J, Bruguera A, Martín-Iguacel R, Raventos B, Llibre JM, Imaz A, Peraire J, Orti AJ, Dalmau D, Casabona J, Miró JM, Falcó V; PISCIS study group. Burgos J, et al. J Antimicrob Chemother. 2022 Dec 23;78(1):108-116. doi: 10.1093/jac/dkac361. J Antimicrob Chemother. 2022. PMID: 36308326
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM; PISCIS study group. Nomah DK, et al. J Antimicrob Chemother. 2022 Jul 28;77(8):2265-2273. doi: 10.1093/jac/dkac177. J Antimicrob Chemother. 2022. PMID: 35678461 Free PMC article.
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review.
Palacio-Vieira J, Reyes-Urueña JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaró I, Borràs FH, Falcó V, Riera M, Domingo P, de Lazzari E, Miró JM, Casabona J; PICIS study group. Palacio-Vieira J, et al. BMC Public Health. 2021 Aug 28;21(1):1596. doi: 10.1186/s12889-021-11613-y. BMC Public Health. 2021. PMID: 34454444 Free PMC article. Review.
Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands.
Bruguera A, Nomah D, Moreno-Fornés S, Díaz Y, Aceitón J, Reyes-Urueña J, Ambrosioni J, Llibre JM, Falcó V, Imaz A, Fanjul F, Navarro G, Pere D, León E, Mera A, Miró JM, Casabona J; PISCIS Cohort Group. Bruguera A, et al. Int J Epidemiol. 2023 Aug 2;52(4):e241-e252. doi: 10.1093/ije/dyad083. Int J Epidemiol. 2023. PMID: 37403345 No abstract available.
Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV.
Teira R, Diaz-Cuervo H, Aragão F, Marguet S, de la Fuente B, Muñoz MJ, Abdulghani N, Ribera E, Domingo P, Deig E, Peraire J, Roca B, Montero M, Galindo MJ, Romero A, Espinosa N, Lozano F, Merino MD, Martínez E, Geijo P, Estrada V, García J, Sepúlveda MA, Berenguer J. Teira R, et al. Among authors: abdulghani n. PLoS One. 2021 Apr 8;16(4):e0249515. doi: 10.1371/journal.pone.0249515. eCollection 2021. PLoS One. 2021. PMID: 33831047 Free PMC article.
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Llibre JM, Domingo P, Falcó V, Imaz A, Cortés C, Force L, Letang E, Vilaró I, Casabona J, Miro JM; PISCIS study group. Nomah DK, et al. Lancet HIV. 2021 Nov;8(11):e701-e710. doi: 10.1016/S2352-3018(21)00240-X. Epub 2021 Oct 13. Lancet HIV. 2021. PMID: 34655549 Free PMC article.
18 results